Related Experiment Video

Updated: Jan 15, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

842

Counter-Therapeutic Strategies for Resistance of FLT3 Inhibitors in Acute Myeloid Leukemia

Moo-Kon Song1

  • 1Division of Hematology-Oncology, Department of Internal Medicine, Haeundae Bumin Hospital, Busan 48094, Republic of Korea.

Cells
|October 15, 2025
PubMed

Insights

FMS-like tyrosine kinase 3 (FLT3) mutations in acute myeloid leukemia (AML) drive poor prognosis. Understanding resistance mechanisms to FLT3 inhibitors is key to developing new treatments for AML patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • FMS-like tyrosine kinase 3 (FLT3) mutations are common in acute myeloid leukemia (AML), correlating with poor prognosis and increased relapse risk.
  • FLT3 inhibitors have shown efficacy but face challenges due to primary and secondary resistance mechanisms, limiting remission rates to 30-40%.

Purpose of the Study:

  • To investigate the mechanisms of resistance to FLT3 inhibitors in AML.
  • To identify strategies for overcoming resistance and improving treatment outcomes for AML patients with FLT3 mutations.

Main Methods:

  • Characterization of resistance signaling pathways in FLT3-mutated AML.
  • Analysis of clinical trial data for FLT3 inhibitor efficacy and resistance patterns.

Main Results:

  • Resistance to FLT3 inhibitors in AML is multifactorial, involving both primary and secondary mechanisms.
  • Relapse rates in patients treated with FLT3 inhibitors range from approximately 30% to 50%.

Conclusions:

  • Elucidating resistance mechanisms provides crucial insights for developing novel FLT3 tyrosine kinase inhibitors (TKIs).
  • Targeting alternative pathways through combination therapies or multiple TKIs may overcome resistance in refractory AML clones.
Keywords:
FMS-like tyrosine kinase 3acute myeloid leukemiatherapeutic resistancetyrosine kinase inhibitors

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.6K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K